FDA approves Acatvis' generic Duragesic patch

MORRISTOWN, N.J. Actavis, the generic pharmaceutical company announced today that it has received approval from the Food and Drug Administration to market Fentanyl, the generic equivalent of the pain patch Duragesic.

President and chief executive officer Robert Wessmann said, "The addition of transdermal fentanyl is representative of our continued effort to expand the depth and breadth of our product portfolio, and highlights our product development expertise in specialty generic products."

Annually, the brand and generic sales of Fentanyl in the U.S. were approximately $1.2 billion for the twelve months ending June 2007 according to IMS health data.